Baird analyst Catherine Schulte raised the firm’s price target on Bio-Techne (TECH) to $88 from $86 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH: